<DOC>
	<DOCNO>NCT00251511</DOCNO>
	<brief_summary>This Phase II , open-label , non-randomized study patient low , intermediate-1 , intermediate-2 , high-risk MDS ( define IPSS ) . Each cycle treatment 6 week length . Patients evaluate every 6 week response . Patients treat minimum 12 week even absence response . Following 12 week treatment , patient continue receive study treatment disease progression unacceptable toxicity .</brief_summary>
	<brief_title>A Phase II Trial Trisenox Plus Thalomid Treatment Patients With Myelodysplastic Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>To eligible study , patient must fulfill follow criterion : 1 . Patients must sign IRBapproved informed consent . 2 . Patients low , intermediate1 , intermediate2 , highrisk MDS ( define IPSS ) document diagnosis MDS ( refractory anemia , refractory anemia excess blast , refractory anemia ring sideroblast , refractory anemia mixed lineage dysplasia , chronic myelomonocytic leukemia ) . 3 . Patients must document history transfusion ( pRBC and/or platelet ) receive 60day period prior initial Trisenox treatment protocol . 4 . Patients ECOG Performance Status 0 1 ( see Appendix I ) . 5 . Absolute QT interval 460 msec presence serum potassium magnesium value within normal range . 6 . Patients must &gt; /= 18 year age . 7 . Patients must either child bear potential negative serum pregnancy test within 24 hour prior registration . Patients consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation bilateral oophorectomy ) postmenopausal least 24 month . 8 . For patient childbearing potential , patient agree use 2 reliable form contraception simultaneously least 1 month begin Thalomid therapy , Thalomid therapy , 1 month follow discontinuation Thalomid therapy . 9 . Renal function : creatinine &lt; 1.5 x institutional upper limit normal ( ULN ) , CTCAE Grade 1 . 10 . Hepatic function : bilirubin &lt; /= 1.5 x ULN , CTCAE Grade 1 . AST &lt; /= 2.5 x ULN , CTCAE Grade 1 . 11 . Serum potassium &gt; 4.0mEq/dL serum magnesium &gt; 1.8 mg/dL . Any following criterion make patient ineligible participate study : 1 . Patients receive prior chemotherapy prior therapy either Trisenox Thalomid . 2 . Patients history hypersensitivity arsenic thalidomide component drug . 3 . Patients significant history cardiac disease ( i.e. , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction last 6 month ) . 4 . Patients history torsade de pointes . 5 . Patients plan receive concurrent therapy treat MDS study treatment period . 6 . Patients serious uncontrolled intercurrent medical psychiatric illness , include serious infection . 7 . Patients history malignancy within last 5 year , could affect diagnosis assessment study drug MDS . 8 . Any patient pregnant lactating . 9 . Any patient unable comply requirement study . 10 . Patients peripheral neuropathy &gt; grade 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>